痛泻要方对肠易激综合征模型大鼠血管活性肠肽的影响_医学论文.docVIP

痛泻要方对肠易激综合征模型大鼠血管活性肠肽的影响_医学论文 痛泻要方对肠易激综合征模型大鼠血管活性肠肽的影响_医学论文 【摘要】 目的从胃肠激素的角度研究痛泻要方治疗肠易激综合征的机理。方法32只wistar大鼠随机分成4组：正常对照组，模型对照组、痛泻要方组、得舒特组，后三组大鼠采用束缚应激刺激加灌服番泻叶煎剂的方法造成肠易激综合征(IBS)大鼠模型，观察痛泻要方对肠易激综合征模型大鼠体内胃肠激素血管活性肠肽（VIP）的影响。结果模型对照血浆及局部肠组织中VIP含量与正常对照组比较，均有统计学意义（0.05～0.01）。痛泻要方组血浆VIP含量与模型对照组比较显著降低，有统计学意义（0.01）；痛泻要方组局部肠组织中VIP含量与模型对照组比较亦有统计学意义（0.05）。结论 IBS模型大鼠体内存在VIP水平升高的病理状态，痛泻要方可调控胃肠激素VIP的分泌和释放，进而达到治疗目的。 【关键词】 痛泻要方 肠易激综合征 大鼠 血管活性肠肽 　　Abstract：ObjectiveTo explore the mechanism of Tongxieyaofang in the treatment of irritable bowel syndrome from the perspective of gastrointestinal hormone.Methods32 wistar rats were divided randomly into 4 groups:normal control group,model control group, Tongxieyaofang group and Dicetel group.Using the methods of binding,stress and stimulation adding taking senna decoction in the later 3 groups of rats,the rats model of irritable bowel syndrome (IBS) was made.To observe the effects of Tongxieyaofang on gastrointestinal hormones( vasoactive intestinal polypeptide,VIP) in rats of IBS.ResultsThe contents of VIP in plasma and intestinal tissue in model group were higher than those in normal group（0.05～0.01）. The concentrations of plasma VIP in Tongxieyaofang group decreased more than those in model group（0.01）, and the contents of VIP in intestinal tissue in Tongxieyaofang group were also lower than those in model group(0.05).ConclusionThe pathological state of the higher levels of VIP exists in rats model of IBS. Tongxieyaofang can treat IBS probably by adjusting the secretion and release of gastrointestinal hormone (VIP). 　　Key words： Tongxieyaofang Iritable bowel syndrome Rats Vasoactive intestinal polypeptide 　　痛泻要方为《景岳全书》所载的经典名方，由白术、白芍、陈皮和防风组成， 具有健脾舒肝、止痛止泻的作用，目前临床主要用于肝郁脾虚型肠易激综合征(irritable bowel syndrome,IBS)的治疗。近年来，国内外的研究发现，IBS的发病与胃肠激素水平密切相关，胃肠激素通过干扰胃肠道的动力与分泌吸收功能而对IBS产生了一定的影响。为了研究痛泻要方的治疗作用及探讨其作用机理，笔者复制出IBS大鼠模型，观察痛泻要方对大鼠血浆及局部肠组织中胃肠激素血管活性肠肽（vasoactive intestinal polypeptide,VIP）水平的影响，探讨其作用机制，为其临床应用提供实验依据。 　　1 材料 　　1.1 动物 Wistar大鼠32只，清洁级，雌雄各半，体